Acadia Pharms Inc Drug Patent Portfolio
Acadia Pharms Inc owns 2 orange book drugs protected by 24 US patents Given below is the list of Acadia Pharms Inc's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11827600 | Crystalline forms of trofinetide | 12 Jul, 2042 | Active |
| US11370755 | Compositions of trofinetide | 03 Aug, 2040 | Active |
| US10449185 | Formulations of pimavanserin | 27 Aug, 2038 | Active |
| US10646480 | Formulations of pimavanserin | 27 Aug, 2038 | Active |
| US10849891 | Formulations of pimavanserin | 27 Aug, 2038 | Active |
| US11452721 | Formulations of pimavanserin | 27 Aug, 2038 | Active |
| US10517860 | Combination of pimavanserin and cytochrome P450 modulators | 23 Mar, 2037 | Active |
| US10953000 | Combination of pimavanserin and cytochrome P450 modulators | 23 Mar, 2037 | Active |
| US9212204 | Treatment of rett syndrome using glycyl-L-2-methylprolyl-L-glutamic acid | 27 Jan, 2032 | Active |
| US7601740 | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases | 29 Apr, 2030 | Active |
| US7732615 | N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms | 03 Jun, 2028 | Active |
| US7659285 | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases | 24 Aug, 2026 | Active |
| US7923564 | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its tartrate salt and crystalline forms | 26 Sep, 2025 | Active |
| US10028944 | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases | 15 Jan, 2024 | Expired |
| US8618130 | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases | 15 Jan, 2024 | Expired |
| US8921393 | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases | 15 Jan, 2024 | Expired |
| US9566271 | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases | 15 Jan, 2024 | Expired |
| US9765053 | Methods of treatment using selective 5-HT2A inverse agonists | 27 Jul, 2022 | Expired |
| US7115634 | 4-aminopiperidine and their use as a medicine | 06 Oct, 2021 | Expired |
| US6756393 | Azacyclic compounds | 06 Mar, 2021 | Expired |
| US6815458 | Azacyclic compounds | 06 Mar, 2021 | Expired |
| US9296694 | Azacyclic compounds | 06 Mar, 2021 | Expired |
| US7858789 | Derivatives of 4-aminopiperidine and their use as a medicament | 13 Dec, 2020 | Expired |
| US8110574 | Derivatives of 4-aminopiperidine and their use as a medicament | 13 Dec, 2020 | Expired |
Latest Legal Activities on Acadia Pharms Inc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Acadia Pharms Inc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Electronic Review
Critical
| 07 Jun, 2024 | US7601740 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 03 Jun, 2024 | US10849891 |
|
Email Notification
Critical
| 06 May, 2024 | US7601740 |
|
Expire Patent
Critical
| 06 May, 2024 | US9296694 |
|
Email Notification
Critical
| 02 May, 2024 | US7601740 |
| Mail O.P. Petition Decision | 02 May, 2024 | US7601740 |
|
Mail-Petition Decision - Dismissed
Critical
| 30 Apr, 2024 | US7601740 |
| O.P. Petition Decision | 29 Apr, 2024 | US7601740 |
|
Petition Decision - Dismissed
Critical
| 29 Apr, 2024 | US7601740 |
| Second letter to regulating agency to determine regulatory review period | 03 Apr, 2024 | US9212204 |
| Petition Entered | 15 Mar, 2024 | US7601740 |
|
Expire Patent
Critical
| 11 Mar, 2024 | US8110574 |
| Letter from FDA or Dept of Agriculture re PTE application | 24 Jan, 2024 | US9212204 |
|
Email Notification
Critical
| 18 Jan, 2024 | US7601740 |
| Mail O.P. Petition Decision | 18 Jan, 2024 | US7601740 |
Acadia Pharms Inc's Family Patents
Acadia Pharms Inc drugs have patent protection in a total of 31 countries. It's US patent count contributes only to 35.6% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click
below to unlock the full patent family tree.
Acadia Pharms Inc Drug List
Given below is the complete list of Acadia Pharms Inc's drugs and the patents protecting them.
1. Daybue
Daybue is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11827600 | Crystalline forms of trofinetide |
12 Jul, 2042
(17 years from now)
| Active |
| US11370755 | Compositions of trofinetide |
03 Aug, 2040
(15 years from now)
| Active |
| US9212204 | Treatment of rett syndrome using glycyl-L-2-methylprolyl-L-glutamic acid |
27 Jan, 2032
(7 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Daybue's drug page
2. Nuplazid
Nuplazid is protected by 21 patents, out of which 11 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10449185 | Formulations of pimavanserin |
27 Aug, 2038
(13 years from now)
| Active |
| US10646480 | Formulations of pimavanserin |
27 Aug, 2038
(13 years from now)
| Active |
| US10849891 | Formulations of pimavanserin |
27 Aug, 2038
(13 years from now)
| Active |
| US11452721 | Formulations of pimavanserin |
27 Aug, 2038
(13 years from now)
| Active |
| US10517860 | Combination of pimavanserin and cytochrome P450 modulators |
23 Mar, 2037
(12 years from now)
| Active |
| US10953000 | Combination of pimavanserin and cytochrome P450 modulators |
23 Mar, 2037
(12 years from now)
| Active |
| US7601740 | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
29 Apr, 2030
(5 years from now)
| Active |
| US7732615 | N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms |
03 Jun, 2028
(3 years from now)
| Active |
| US7659285 | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
24 Aug, 2026
(1 year, 9 months from now)
| Active |
| US7923564 | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its tartrate salt and crystalline forms |
26 Sep, 2025
(10 months from now)
| Active |
| US10028944 | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
15 Jan, 2024
(10 months ago)
| Expired |
| US8618130 | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
15 Jan, 2024
(10 months ago)
| Expired |
| US8921393 | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
15 Jan, 2024
(10 months ago)
| Expired |
| US9566271 | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
15 Jan, 2024
(10 months ago)
| Expired |
| US9765053 | Methods of treatment using selective 5-HT2A inverse agonists |
27 Jul, 2022
(2 years ago)
| Expired |
| US7115634 | 4-aminopiperidine and their use as a medicine |
06 Oct, 2021
(3 years ago)
| Expired |
| US6756393 | Azacyclic compounds |
06 Mar, 2021
(3 years ago)
| Expired |
| US6815458 | Azacyclic compounds |
06 Mar, 2021
(3 years ago)
| Expired |
| US9296694 | Azacyclic compounds |
06 Mar, 2021
(3 years ago)
| Expired |
| US7858789 | Derivatives of 4-aminopiperidine and their use as a medicament |
13 Dec, 2020
(3 years ago)
| Expired |
| US8110574 | Derivatives of 4-aminopiperidine and their use as a medicament |
13 Dec, 2020
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nuplazid's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List